| [1] |
Leung WK,Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice[J]. Lancet Oncol,2008,9(3):279-87.
|
| [2] |
Varadhachary G, Ajani JA. Gastric cancer[J]. Clin Adv Hematol Oncol,2005,3(2):118-24.
|
| [3] |
Rosati G, Ferrara D, Manzione L. New perspectives in the treatment of advanced or metastatic gastric cancer[J]. World J Gastroenterol,2009,15(22):2689-92.
|
| [4] |
Tanabe K, Suzuki T, Tokumoto N, et al. Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a restrospective analysis[J]. World J Surg Oncol,2010,8:40.
|
| [5] |
O’Dwyer PJ, Johnson SW. Current status of oxaliplatin in colorectal cancer[J]. Semin Oncol,2003,30(3 Suppl 6):78-87.
|
| [6] |
Ajani JA, Rodriquez W, Bodoky G, et al. Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusiona1 fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial[J]. J Clin Oncol,2010,28(9):1547-53.
|
| [7] |
Saeki T, Takashima S. Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine[J]. Gan To Kagaku Ryoho,1999,26(4):447-55.
|
| [8] |
Cassidy J,Tabernero J,Twelves C,et al. XELOX (capecitsbine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer[J]. J Clin Oncol,2004,22(11):2084-91.
|
| [9] |
Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase Ⅲ trail conducted in patients with advanced colorectal carcinoma[J]. Eur J Cancer,2001,37(5):597-604.
|
| [10] |
Lee JL, Kang YK, Kang HJ, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer[J]. Br J Cancer,2008,99(4):584-90.
|
| [11] |
Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer[J]. Cancer Chemother Pharmacol,2008,61(4): 62 3-9.
|
| [12] |
Maehara Y. S-1 in gastric cancer: a comprehensive review[J]. Gastric Cancer,2003,6 Suppl 1:2-8.
|
| [13] |
Tanaka F, Fukuse T, Wada H, et al. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeuic agents[J]. Curr Pharm Biotechnol,2000,1(2):137-64.
|
| [14] |
Terashima M, Fujiwara H, Takagane A, et al. Rediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer[J]. Gastric Cancer,2003,6 Suppl 1: 71-81.
|
| [15] |
Yoshisue K, Hironaga K, Yamaguehi S, et al. Reduction of 5- fluorou-racil(5-FU) gastrointestinal(GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate(Oxo) in rats[J]. Cancer Chemother Pharmacol,2000,46(1):51-6.
|
| [16] |
Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial): a phase Ⅲ trial[J]. Lancet Oncol,2008,9(3):215-21.
|
| [17] |
Jin M, Lu H, Li J, et al. Randomized 3-armed phase Ⅲ study of S-1 monotherapy versus S-1/CDDP(SP) versus 5-FU/CDDP ( FP) in patients(pts) with advanced gastric cancer(AGC):SC101 study[J]. J Clin Oncol,2008,26:(Abstr:4533).
|
| [18] |
Park I, Lee JL, Ryu MH,et al. PhaseⅠ/Ⅱ and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer[J]. Cancer Chemother Pharmacol,2010,65(3):473-80.
|
| [19] |
Kim C, Lee JL, Ryu MH, et al. A prospective phaseⅡstudy of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer[J]. Invest New Drugs,2011,29(2):366-73.
|
| [20] |
Milano G, Etienne-Grimaldi MC, Mari M, et al. Candidate mechanisms for capecitabine-related hand-foot syndrome[J]. Br J Clin Pharmacol,2008,66(1):88-95.
|
| [21] |
Saif MW. Capecitabine and hand-foot syndrome[J]. Expert Opin Drug Saf,2011,10(2):159-69.
|
下载:
